NAV

Dabigatran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Dabigatran
DrugBank Accession Number
DB14726
Background

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Type
Small Molecule
Groups
Approved, Investigational
Structure
3D
Similar Structures
Weight
Average: 471.521
Monoisotopic: 471.201887693
Chemical Formula
C25H25N7O3
Synonyms
  • Dabigatran
External IDs
  • BIBR 953 ZW
  • BIBR-953
  • BIBR-953-ZW
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Dabigatran.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dabigatran.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Dabigatran.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran.
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Pradaxa

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
I0VM4M70GC
CAS number
211914-51-1
InChI Key
YBSJFWOBGCMAKL-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
IUPAC Name
3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid
SMILES
CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1

References

General References
Not Available
KEGG Drug
D09707
ChemSpider
187412
BindingDB
50112086
RxNav
1546356
ChEBI
70752
ChEMBL
CHEMBL48361
ZINC
ZINC000001910616
PDBe Ligand
4CC
Wikipedia
Dabigatran
PDB Entries
4jn2 / 4yhi / 4yhk / 4yhm / 4yho

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionAtrial Fibrillation / Device Related Thrombus / Left Atrial Appendage Thrombosis / Watchman LAA Closure Device1
4CompletedBasic ScienceAcute Coronary Syndrome (ACS) / Atrial Fibrillation1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedOtherCerebral Ischemic Events / Cognitive Dysfunctions / Dementia1
4CompletedOtherPost-operative Atrial Fibrillation (POAF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0975 mg/mLALOGPS
logP2.37ALOGPS
logP0.077Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.18Chemaxon
pKa (Strongest Basic)12.52Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area150.22 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity143.26 m3·mol-1Chemaxon
Polarizability50.96 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ab9-0005900000-230e069a463f8a243ca0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0bt9-0011900000-9797122d6f33a08ccfaf
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0029000000-db6eb4b25c6043ab60bc
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0934200000-9b2a52a2114822892916
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00mk-0019100000-80f33672d0773f800222
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-002f-9358100000-a8df6ead44eceff6f6f9
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-238.4969138
predicted
DarkChem Lite v0.1.0
[M+H]+238.8455138
predicted
DarkChem Lite v0.1.0
[M+Na]+238.2521138
predicted
DarkChem Lite v0.1.0

Drug created at December 14, 2018 17:30 / Updated at June 26, 2021 13:10